Medindia

X

Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.

Wednesday, December 31, 2008 General News J E 4
Advertisement
NEW BRUNSWICK, N.J., Dec. 30 Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Omrix Biopharmaceuticals, Inc., a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products. Omrix is expected to operate as a stand-alone entity reporting through ETHICON, Inc., a Johnson & Johnson company.



About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.



SOURCE Johnson & Johnson
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Stop & Shop Supermarket Announces Free Antibiotic ...
S
eDiets.com(R) Appoints Kevin N. McGrath as Preside...